<DOC>
	<DOCNO>NCT02871271</DOCNO>
	<brief_summary>The purpose study evaluate tolerability benefit IQP-AS-121 reduce fatigue tiredness improve mental alertness .</brief_summary>
	<brief_title>Tolerability Benefit IQP-AS-121 Fatigue Mental Alertness</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<criteria>1 . Caucasian male female , 2155 year age 2 . Body mass index ( BMI ) 18.529.9 kg/m2 3 . Generally good health without clinically significant finding screen 4 . No chronic fatigue syndrome accord Fukuda Centres Disease Control Prevention ( CDC ) criteria screen 5 . Subjective feeling chronic stress tiredness 312 last month prior screen 6 . Screening Scale Chronic Stress ( SSCS ) score &gt; 18 7 . Fatigue Severity Scale score &gt; 4 8 . ≤ 3 cups/portions coffee and/or caffeinecontaining food/beverages per day 3 last month prior screen study 9 . Regular stable continuous level daily activity 10 . Regular sleepwake cycle 11 . Normal dietary habit accord investigator 's judgement 12 . ≤ moderate level physical exercise 13 . Readiness comply study procedure , particular : Consumption IP treatment period Filling questionnaires Keep habitual diet level physical exercise 14 . No change smoke habit study 15 . Women childbearing potential : 1. negative pregnancy test ( ßHCG urine screen ) 2. commitment use reliable contraception method entire study Participation base upon write informed consent form ( ICF ) participant follow write oral information investigator regard nature , purpose , consequence possible risk clinical study . 1 . Known sensitivity component IP 2 . Any medical condition associate tiredness ( e.g . iron deficiency , hypotension etc . ) 3 . History and/or presence clinically significant disease , per investigator 's judgement could interfere result study safety subject : 1 . Psychiatric disease , e.g . depression , schizophrenia 2 . Eating disorder anorexia 3 . Untreated nonstabilized metabolic disease , e.g . diabetes mellitus 4 . Untreated nonstabilized thyroid disorder 5 . Untreated nonstabilized hypertension ( systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg ) 6 . Significant gastrointestinal disease 7 . Insomnia 8 . Known bleed disorder haemophilia 9 . Any known significant serious condition / disease render subject ineligible ( e.g . history malignancy within past 5 year prior screen , clinically significant cardiovascular , renal , liver disease etc . ) 4 . Use medication investigator 's judgement could interfere result study ( e.g . psychoactive medication , statin , proton pump inhibitor , bloodpressure medication , antihistamine , antibiotic , diuretic ) within last 4 week prior screen study 5 . Consumption vitamin , nutritional supplement , supplementary balance diet , mineral product investigator 's judgement could interfere result study within last 4 week prior screen study 6 . Consumption adaptogens ( e.g . ginseng Schisandra ) St. John 's Wort within last 4 week prior screen study 7 . Consumption energy drink study 8 . Start use contraception medication last 3 month prior screen study 9 . Use anticoagulant warfarin 10 . Clinically significant deviation laboratory parameter and/or deviation &gt; 2 x ULN ( upper limit normal ) screen 11 . Recent current significant stressor ( e.g . active grieving ) 12 . Chronic pain 13 . Chronic sleep deficiency ( &lt; 5 hours/night ) 14 . Alcohol abuse ( men : ≥21 units/week , woman : ≥14 units/ week ; 1 unit equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 15 . Drug abuse 16 . Participation another study last 30 day prior screen 17 . Women childbearing potential : pregnant breastfeed 18 . Any situation expect study cause acute high level stress 19 . Any reason deem suitable exclusion per investigator 's judgment , e.g . insufficient compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>